Objective. Systemic inflammation response index (SIRI) is a new inflammation-based evaluation system that has been reported for predicting survival in multiple tumors, but the prognostic significance of SIRI in cancers has not been evinced. Methods. Eligible studies updated on December 31, 2019, were selected according to inclusion criteria, the literature searching was performed in PubMed, Web of Science, Google Scholar, and Cochrane. Hazard ratios (HRs), and 95% confidence intervals (CIs) were extracted and pooled by using Stata/SE 14.1. Results. 11 publications involving 19 cohort studies with a total of 5,605 subjects were included. Meta-analysis results evinced that high SIRI was associated with worse OS (, 95% CI: 1.87-2.83, ), poor CSS/DSS (, 95% CI: 1.98-4.04, ), and inferior MFS/DFS/PFS/RFS/TTP (, 95% CI: 1.65-2.15, ). The association of SIRI with OS was not significantly affected when stratified by diverse confounding factors. It was suggested that tumor patients with high pretreatment SIRI levels would suffer from adverse outcomes. Conclusion. High SIRI is associated with unfavorable clinical outcomes in human malignancies; pretreatment SIRI level might be a useful and promising predictive indicator of prognosis in cancers.

中文翻译：

---

癌症患者治疗前全身炎症反应指数预后价值的证据：19 项队列研究的汇总分析。

客观的。全身炎症反应指数 (SIRI) 是一种新的基于炎症的评估系统，已被报道用于预测多种肿瘤的存活率，但 SIRI 在癌症中的预后意义尚未得到证实。方法。根据纳入标准选择了 2019 年 12 月 31 日更新的合格研究，在 PubMed、Web of Science、Google Scholar 和 Cochrane 中进行了文献检索。使用 Stata/SE 14.1 提取和汇总风险比 (HR) 和 95% 置信区间 (CI)。结果。共纳入 11 篇出版物，涉及 19 项队列研究，共 5,605 名受试者。荟萃分析结果表明，高 SIRI 与较差的 OS 相关（, 95% CI: 1.87-2.83,),糟糕的 CSS/DSS (, 95% CI: 1.98-4.04,)和劣质 MFS/DFS/PFS/RFS/TTP (, 95% CI: 1.65-2.15,）。当通过多种混杂因素进行分层时，SIRI 与 OS 的关联没有显着影响。有人提出，治疗前 SIRI 水平高的肿瘤患者会出现不良后果。结论。高 SIRI 与人类恶性肿瘤的不利临床结果相关；治疗前 SIRI 水平可能是癌症预后的有用且有希望的预测指标。